Southeast Retina Center

Southeast Retina Center is a leading regional retina-focused specialty practice and research site, participating as an investigator site in numerous Phase I-III and post-marketing (Phase IV) clinical trials for ophthalmic therapies, notably those treating wet and dry age-related macular degeneration, diabetic retinopathy, and other retinal diseases. Their research includes anti-VEGF biologics, gene therapies, implantable drug delivery devices, and antisense oligonucleotides. The practice is recognized for contributing to the development and early clinical experience of several FDA-approved retina treatments, including the port delivery system for ranibizumab.